ELVN — Enliven Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1672619 ·
Last close
$44.86
Market Cap
$3.13B
52W High
$48.53
52W Low
$26.70
ADV30
1,302,908
Next earnings
2026-05-13
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,823,000 | -23,627,000 | 464,852,000 | 132,184,000 | 11,487,000 |
| Dec 2025 | 0 | — | -34,285,000 | -29,667,000 | 476,168,000 | 98,896,000 | 16,568,000 |
| Sep 2025 | 0 | — | -25,096,000 | -20,148,000 | 490,875,000 | 101,732,000 | 14,753,000 |
| Jun 2025 | 0 | — | -28,584,000 | -25,335,000 | 503,887,000 | 119,437,000 | 15,415,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-70,301,000
Investing CF
$-173,841,000
Financing CF
$218,867,000
CapEx
$-181,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.86
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-347,166,000
Inventory
—
Receivables
—
ST Investments
$363,725,000
EBIT TTM
$-119,658,000
Pretax Income TTM
$-103,694,000
Interest Exp TTM
—
Analysts
7
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -119,658,000 | -103,694,000 | 476,168,000 | 16,568,000 | — | -70,301,000 |
| Dec 2024 | 0 | -104,554,000 | -89,024,000 | 325,760,000 | 15,915,000 | — | -73,192,000 |
| Dec 2023 | 0 | -83,529,000 | -71,584,000 | 271,867,000 | 25,961,000 | — | -61,269,000 |
| Dec 2022 | 0 | -38,791,000 | -37,662,000 | 83,298,000 | 160,123,000 | — | -32,077,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.43
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $25.00 · spot: $44.86 · call volume: 192 · put volume: 0Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | $3.17B | $19.20 | — |
| GPCR | Structure Therapeutics Inc. | $3.20B | $45.00 | — |
| QURE | uniQure N.V. | $3.04B | $48.16 | — |
| RCUS | Arcus Biosciences, Inc. | $3.03B | $24.12 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.28B | $26.22 | — |
News headlines (Yahoo Finance, 1h cache)
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
2026-06-15 20:40 · Yahoo
Enliven Therapeutics (ELVN) Soars on Stellar Leukemia Drug Trial
2026-06-13 07:02 · Yahoo
ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development
2026-06-12 18:22 · Yahoo
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of SpaceX Debut
2026-06-12 13:15 · Yahoo
Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants
2026-06-12 02:37 · Yahoo
Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
2026-06-11 20:05 · Yahoo
Enliven Therapeutics Reports Positive Phase 1 CML Data and FDA Alignment for Phase 3 Trial (ELVN)
2026-06-11 14:36 · Yahoo
Enliven Therapeutics Says Aligned With US FDA on Dose Recommendation for Late-Stage Chronic Myeloid Leukemia Trial
2026-06-11 13:11 · Yahoo
Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components
2026-06-11 12:00 · Yahoo
J&J looks to widen Imaavy’s use; $300M backs rare disease drug launch
2026-06-11 09:27 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.